On this page
Amrutanjan Health targets 100,000 direct chemist outlets in FY27
Our read
Amrutanjan’s FY27 outlet push is likely to increase sales reach materially, but investor upside depends on whether new chemists become high-frequency reorder accounts rather than low-productivity distribution points.
For operators
Amrutanjan’s push toward 100,000 direct chemist outlets in FY27 will require rapid distributor, field-force and in-store execution upgrades as it expands beyond southern and eastern markets.
Watch
Quarterly disclosure of active direct chemist outlets versus cumulative signed outlets.
Ask next
How do Amrutanjan Health Care's results compare with its rivals?The report,
Amrutanjan Health Care targets 1 lakh direct chemist outlets in FY27 after adding 44,000 in FY26. It is expanding beyond southern and eastern strongholds, relaunching Relief, growing Comfy women’s hygiene, and reported FY26 revenue of ₹502.55 crore and profit of ₹57.92 crore.
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
Reported figures
From the report. Source details below
| FY26 revenue from operations up 11.23% to | ₹502.55 crore |
|---|---|
| FY26 net profit up nearly 14% to | ₹57.92 crore |
| Headache category grew 8%; body-ache category grew | 16% |
| 70% of critical processes automated, targeted near | 100% |
Also in the report
- Pain-management category gross sales grew 10% in FY26
- Comfy ranks fourth nationally in mass pad segment
Other figures
- Over 650 employees
Why it matters to operators
The national chemist-outlet ambition could make regional distribution partnerships or acquisitions attractive to accelerate entry into underpenetrated western and northern markets.
What to watch next
- Revenue growth in FY27 relative to FY26's 11.23% increase.
- Gross margin, employee expense, selling expense and trade-promotion trends.
- Growth contribution from western and northern regions and evidence of reduced geographic concentration.
- Inventory days, receivable days and operating cash-flow conversion as direct coverage scales.
- New product launches and proportion of sales from non-core health-and-wellness categories.
Show 1 more
- Competitive response from larger OTC and consumer-health companies through retailer incentives or price promotions.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Add regional sales personnel, distributors and direct-servicing infrastructure in western and northern India.
- Increase chemist-focused trade schemes, point-of-sale visibility and retailer engagement to secure shelf space.
- Prioritize high-velocity OTC products such as pain balm, headache remedies and cold-relief products to build outlet productivity.
- Use the enlarged direct network to launch or broaden adjacent health-and-wellness SKUs.
- Track outlet activation, repeat ordering and revenue per outlet rather than headline distribution additions alone.
The counter-case
The case against this reading — not reported by the source.
The outlet target may be more a distribution-footprint metric than a demand signal: rapidly adding chemists can dilute sales per outlet, raise distributor/field-force costs, and increase working-capital or promotional spending before revenues catch up. Expansion beyond southern and eastern strongholds also introduces tougher competition, lower brand familiarity, and execution risk. The 11.23% revenue and nearly 14% profit growth are solid but do not by themselves demonstrate that a much broader direct-coverage model will sustain margins.